---
title: "Sphenopalatine Block or Epidural Bloodpatch for Post Dural Puncture Headache: Randomized Controlled Trial"
nct_id: NCT02984618
overall_status: TERMINATED
phase: NA
sponsor: Brasilia University Hospital
study_type: INTERVENTIONAL
primary_condition: Post-Dural Puncture Headache
countries: Brazil
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT02984618.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT02984618"
ct_last_update_post_date: 2020-02-28
last_seen_at: "2026-05-12T06:53:18.285Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Sphenopalatine Block or Epidural Bloodpatch for Post Dural Puncture Headache: Randomized Controlled Trial

**Official Title:** Gabriel Guimaraes: Sphenopalatine Block or Epidural Bloodpatch for Post Dural Puncture Headache: Randomized Controlled Trial

**NCT ID:** [NCT02984618](https://clinicaltrials.gov/study/NCT02984618)

## Key Facts

- **Status:** TERMINATED
- **Why Stopped:** High recurrence of headache in SPG group.
- **Phase:** NA
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 19
- **Lead Sponsor:** Brasilia University Hospital
- **Conditions:** Post-Dural Puncture Headache
- **Start Date:** 2016-12-01
- **Completion Date:** 2019-12-20
- **CT.gov Last Update:** 2020-02-28

## Brief Summary

Introduction: Recently sphenopalatine block emerged as an alternative to epidural blood patch for post dural puncture headache but the investigators do not know if it has significant efficacy when compared to epidural blood patch. Method: randomized trial where patients will randomly receive either sphenopalatine block or epidural blood patch. Pain relief to no pain or low intensity pain will be the main outcome

## Detailed Description

Introduction: Recently sphenopalatine block emerged as an alternative to epidural blood patch for post dural puncture headache but the investigators do not know if it has significant efficacy when compared to epidural blood patch. Method: randomized clinical trial where patients with moderate to severe post dural puncture pain will randomly receive either sphenopalatine block or epidural blood patch. Pain relief to no pain or low intensity pain will be the main outcome. Pain recurrence, survival without pain and side effects (tinitus, low back pain, new dural puncture, sore throat) will be secondary outcomes.

## Eligibility

- **Minimum age:** 18 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* Diagnostic criteria for post dural puncture headache
* Moderate to severe post dural puncture headache

Exclusion Criteria:

* Procedure failures: new dural puncture on epidural blood patch trial, unable to find epidural space, intolerance to insertion of nasal swabs.
* Follow up loss
```

## Arms

- **Treatment group** (EXPERIMENTAL) — Patients will receive sphenopalatine ganglion block with ropivacaine 0.375% 3ml on each side
- **Control group** (ACTIVE_COMPARATOR) — Patients will receive classic epidural blood patch with 20ml of autologous blood

## Interventions

- **Sphenopalatine ganglion block** (PROCEDURE) — Cotton- tipped applicators inserted up through the nose followed by infusion of ligdocaine through the applicators.
- **Epidural blood patch** (PROCEDURE) — Autologous sterile blood (20ml) will be infused in the lombar epidural space.

## Primary Outcomes

- **Pain relief** _(time frame: Pain reduction to no pain or low pain within 30 minutes of the intervention.)_ — Pain assessed by categorical verbal scale (no pain, low pain, moderate pain or severe pain) 30 minutes after the procedure.

## Secondary Outcomes

- **Tinitus** _(time frame: Incidence (dichotomic) of tinutus within 24 hours after the procedure.)_
- **Low back pain** _(time frame: Incidence (dichotomic) of low back pain within 24 hours after the procedure.)_
- **Sore throat** _(time frame: Incidence (dichotomic) of sore throat within 24 hours after the procedure.)_

## Locations (1)

- Hospital Universitário de Brasilia, Brasília, Federal District, Brazil

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.whyStopped` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.hospital universitário de brasilia|brasília|federal district|brazil` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT02984618.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT02984618*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*